Back

CME Outfitters, LLC

  • Carcinoma, Non-Small-Cell Lung

Advancing Health Equity Across the Spectrum: Optimizing Biomarker Usage in NSCLC

Lung cancer disproportionately affects many groups across the United States, including ethnic minorities and poor, rural, and military service individuals, with higher incidence and mortality rates. While there are many factors contributing to this observation, clinicians can address lung cancer inequities in their clinics by optimally utilizing biomarker testing, in order to provide the most effective treatments, and by identifying personal and systemic biases that reduce biomarker testing. In this CME Outfitters BriefCase, expert faculty will use case examples to highlight the current clinical guidelines for biomarker testing and advise learners on addressing ethnic, geographic, and socioeconomic barriers to optimal utilization of biomarker testing in lung cancer.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

ABIM — Medical KnowledgeUp to 1 point

FDA REMS

No

Qualifies for MIPS

Yes

Faculty 1

All faculty
  • Narjust Florez, MD

    Associate Director of The Cancer Care Equity Program, Dana-Farber Cancer Institute

    Medical Oncology

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Commercial Support
  • Released
    Sep 22, 2025
  • Last day to claim credit
    Sep 23, 2028 2 years left